Tag Archives: OncoGenex

October, 2016

August, 2016

  • 17 August

    OncoGenex’s Prostate Cancer Candidate Fails in Late-Stage Trial

    BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 16, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did …

January, 2016

  • 22 January

    OncoGenex’s NSCLC Candidate Fails to Meet PFS Goal in Mid-Stage Trial

    BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 20, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required …